Moderna (MRNA) is one of those names that received a great deal of public attention due to the virus over the past year and a half. Though the biotech company has been in existence for about 10 years, Moderna’s COVID-19 vaccine pushed it into the spotlight.   The resurgent virus and strong global demand for its COVID-19 vaccine turned Moderna profitable, while its stock price skyrocketed over 434% in 2020. Furthermore, it has gained approximately 210% this year. (See Moderna stock charts on TipRanks) Adding to investors’ optimism is its $19.2 billion worth of advance purchase agreements (APAs) for 2021.
https://www.tipranks.com/news/article/moderna-has-rallied-over-200-ytd-is-there-more-upside-left?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Moderna Charts.